ImmuneID develops cutting-edge precision therapeutics by studying unexplored biological reactions to reveal disease drivers. By identifying the binding partners of antibodies, we generate unique, deep datasets of patient immune histories. This distinctive information is integrated with single cell, multi-omics and clinical datasets and probed using complex machine-learning and AI algorithms in our proprietary platform, aiSPIRE, to uniquely uncover hidden disease signatures for novel therapeutic drug discovery.
The immune system is a complex network working to provide protection from a diverse range of pathogens. For reasons that we don’t yet fully understand, the immune system can fail or react in ways that result in serious diseases for which there are few effective therapies currently available.
Our aiSPIRE platform incorporates high-throughput screening with the power of AI and machine learning to elucidate patient subpopulations and disease etiology leading to new insights and target discovery.
Our aiSPIRE platform incorporates high-throughput screening with the power of AI and machine learning to unveil clinical markers, patient subpopulations and disease etiology.
DRIVING LIMITLESS POSSIBILITIES
A future is possible where the mysteries of the immune system are no longer secrets – enabling us to create novel therapies and treatments to give new hope to patients. This bold vision requires fearless people who are driven to make it happen.